Brief: Personalis Selected For Clinical Research After Successful Evaluation Of Whole Genome-Based Molecular Residual Disease Assay
07/03/2023 13:57
March 7 (Reuters) - Personalis Inc PSNL.O :
* PERSONALIS SELECTED FOR CLINICAL RESEARCH AFTER SUCCESSFUL
EVALUATION OF WHOLE GENOME-BASED MOLECULAR RESIDUAL DISEASE
ASSAY
* PERSONALIS INC - COMPANY WILL EXPLORE USE OF NEXT
PERSONAL® IN
ASTRAZENECA TRIAL
Source text for Eikon: ID:nBw2kwpBJa
Further company coverage: PSNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary